264 related articles for article (PubMed ID: 11483229)
1. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
Van Gaal LF; Van Acker KL; De Leeuw IH
Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.
Gerstein HC; Garon J; Joyce C; Rolfe A; Walter CM
Diabet Med; 2004 Nov; 21(11):1200-3. PubMed ID: 15498086
[TBL] [Abstract][Full Text] [Related]
5. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
6. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
[TBL] [Abstract][Full Text] [Related]
7. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Owens DR; Luzio SD; Ismail I; Bayer T
Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
[TBL] [Abstract][Full Text] [Related]
8. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
[TBL] [Abstract][Full Text] [Related]
9. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
Damsbo P; Clauson P; Marbury TC; Windfeld K
Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
[TBL] [Abstract][Full Text] [Related]
10. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
Mafauzy M
Diabetes Res Clin Pract; 2002 Oct; 58(1):45-53. PubMed ID: 12161056
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide as monotherapy in Type 2 diabetes.
Gomis R
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S133-5. PubMed ID: 10522838
[TBL] [Abstract][Full Text] [Related]
13. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
15. Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes.
Kølendorf K; Eriksson J; Birkeland KI; Kjellström T; Hreidarsson AB
Diabetes Res Clin Pract; 2004 Apr; 64(1):33-40. PubMed ID: 15036825
[TBL] [Abstract][Full Text] [Related]
16. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
[TBL] [Abstract][Full Text] [Related]
18. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Nattrass M; Lauritzen T
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
[TBL] [Abstract][Full Text] [Related]
20. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
Landgraf R; Bilo HJ; Müller PG
Eur J Clin Pharmacol; 1999 May; 55(3):165-71. PubMed ID: 10379630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
